Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction

Aging Health

Volumn 4, Issue 1, 2008, Pages 37-46

  Carter, Christy S ^a   Groban, Leanne ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; ACE polymorphisms; Aging; Angiotensin receptor blockers; Diastolic dysfunction; Disability; Exercise capacity; Renin agiotensin system; Sarcopenia

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; INDAPAMIDE; INSULIN; INTERLEUKIN 6 ANTIBODY; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

AGING; BODY COMPOSITION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DAILY LIFE ACTIVITY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENDURANCE; ENZYME ACTIVITY; ENZYME ANALYSIS; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENOTYPE; GERIATRIC DISORDER; HEART ATRIUM FIBRILLATION; HEMODYNAMICS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LUNG CONGESTION; LUNG EDEMA; METABOLIC REGULATION; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE TRAINING; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL CAPACITY; PHYSICAL PERFORMANCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; WALKING SPEED; WASTING SYNDROME;

EID: 39349102199     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.4.1.37     Document Type: Review

References (93)

1. de Cavanagh EM, Inserra F, Ferder M, Ferrier L: From mituchondria to disease: role of the renin-angiotensin system. Am. J. Nephrol. 27(6), 545-553 (2007).
2. Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35(6), 1270-1277 (2000).
3. Newman AB, Haggerty CL, Goodpaster B et al.: Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. J. Am. Geriatr. Soc. 51(3), 323-330 (2003).
4. Broadwin J, Goodman-Gruen D, Slymen D: Ability of fat and fat-free mass percentages to predict functional disability in older men and women. J Am. Geriatr. Soc. 49(12), 1641-1645 (2001).
5. Sternfeld B, Ngo L, Satariano WA, Tager IB: Associations of body composition with physical performance and self-reported functional limitation in elderly men and women. Am. J. Epidemiol. 156(2), 110-121 (2002).
6. Visser M, Langlois J, Guralnik JM et al.: High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am. J. Clin. Nutr. 68(3), 584-590 (1998).
7. Carter CS, Cesari M, Ambrosius WT et al.: Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J. Gerontol. A Biol. Sci. Med. Sci. 59(5). 416-423 (2004).
8. Gallagher D, Ruts E, Visser M et al.: Weight stability masks sarcopenia in elderly men and women. Am. J. Physiol. Endocrinol. Metab. 279(2), E366-E375 (2000).
9. Onder G, Penninx BW, Balkrishnan R et al.: Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 359(9310), 926-930 (2002).
10. Di BM, van de Poll-Franse LV, Onder G et al.: Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J. Am. Geriatr. Soc. 52(6), 961-966 (2004).
11. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273(18), 1450-1456 (1995).
12. Gambassi G, Lapane KL, Sgadari A et al.; for the SAGE Study Group: Effects of anglotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Arch. Intern. Med. 160(1), 53-160 (2000).
13. PROGRESS.: Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial. Stroke 34(10), 2333-2338 (2003).
14. Danser AH, Schalekamp MA, Bax WA et al.: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92(6), 1387-1388 (1995).
15. Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery H: Human angiotensin I-converting enzyme gene and endurance performance. J. Appl. Physiol. 87(4), 11313-1316 (1999).
16. Gayagay G, Yu B, Hambly B et al.: Elite endurance athletes and the ACE I allele - the role of genes in athletic performance. Hum Cenet. 103(1), 48-50 (1998).
17. Woods DR, Montgomery HE: Angiotensin-converting enzyme and genetics at high altitude. High Alt. Med. Biol. 2(2), 201-210 (2001).
18. Woods DR, Brull D, Montgomery HE: Endurance and the ACE I/D polymorphism. Sci. Prog. 83(Pt 4), 317-336 (2000).
19. Montgomery H, Clarkson P, Barnard M et al.: Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet 353(9152), 541-545 (1999).
20. Rankinen T, Wolfarth B, Simoneau JA et al.: No association between the angiotensin-converting enzyme ID polymorphism, and elite endurance athlete status. J. Appl. Physiol. 88(5), 1571-1575 (2000).
21. Kritchevsky SB, Nicklas BJ, Visser M et al.: Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA 294(6), 691-698 (2005).
22. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277(6 Pt 1), E1130-E1141 (1999).
23. Goodpaster BH, Carlson CL, Visser M et al.: Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J. Appl. Physiol. 90(6), 2157-2165 (2001).
24. de Cavanagh EM, Ferder L, Carrasquedo F et al.: Higher levels of antioxidant defenses, in enalapril-treated versus non-enalapril-treated hemodialysis patients. Am. J. kidney Dis. 34(3), 445-455 (1999).
25. de Cavanagh EM, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG: Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett. 361(1), 22-24 (1995).
26. de Cavanagh EM, Fraga CG, Ferder L, Inserra F: Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am. J. Pbysiol. 272(2 Pt 2), R514-R518 (1997).
27. de Cavanagh EM, Inserra F, Ferder L, Fraga CG: Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278(3), R572-R577 (2000).
28. de Cavanagh EM, Inserra F, Toblli J, Stella I, Fraga CC, Ferder L: Enalapril attenuates oxidative stress in diabetic rats. Hypertension. 38(5), 1130-1136 (2001).
29. Zhao W, Diz DI, Robbins ME: Oxidative damage pathways in relation to normal tissue injury. Br. J. Radiol. 80 Spec. No. 1, S23-S31 (2007).
30. Muller DN, Fiebeler A, Park JK, Dechend R, Luft FC: Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage. Clin. Nephrol. 60(Suppl. 1), S2-12 (2003).
31. Godsei LM, Leon JS, Wang K, Fornek JL, Molteni A, Engman DM: Captopril prevents experimental autoimmune myocarditis. J. Immmunol. 171(1), 346-352 (2003).
32. Leon JS. Wang K, Engman DM: Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107(17), 2264-2269 (2003).
33. Kuno A, Yamada T, Masuda K et al.: Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 124(4), 1010-1019 (2003).
34. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA: Modulation of cutaneous inflammation by angiotensin-converting enzyme. J. Immunol. 170(7), 3866-3873 (2003).
35. Tabet JY, Lopes ME, Champagne S, Su JB, Merlet P, Hittinger L: Inflammation, cytokines and anti-inflammatory therapies in heart failure. Arch. Mal. Coeur. Vaiss. 95(3), 204-212 (2002).
36. Decarie A, Adam A, Couture R: Effects of captopril and Icatibant on bradykinin (BK) and des (Arg9) BK in carrageenan-induced edema. Peptides 17(6), 1009-1015 (1996).
37. Johnston CI: Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 23(2). 258-268 (1994).
38. Rezkalla S, Kioner RA, Khatib G, Khatib R: Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 81(3), 1039-1046 (1990).
39. Goodpaster BH, Krishnaswami S, Resnick H et al.: Association between regional adipose tissue distribution and both Type 2 diabetes and impaired glucose tolerance in elderly men and women. DiabetesCare 26(2), 372-379 (2003).
40. Kelley DE, Goodpaster BH, Storlien L: Muscle triglyceride and insulin resistance. Annu. Rev. Nutr. 22, 325-346 (2002).
41. Henriksen EJ, Jacob S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44(2), 267-272 (1995).
42. Foianini KR, Steen MS, Kinnick TR, Schmit MB, Youngblood EB, Henriksen EJ: Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle. J. Appl. Physiol. 89(2), 687-694 (2000).
43. Leighton B, Sanderson AL, Young ME, Radda GK, Boehm EA, Clark JF: Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 45(Suppl. 1), S120-S124 (1996).
44. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38(4), 884-890 (2001).
45. Sasaki K, Kushiro T, Nakagawa S, Kanmatsuse K: Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats. Nippon Jinzo Gakkai Shi 41(7), 692-696 (1999).
46. Higashiura. K, Ura N, Takada T et al.: The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am. J Hypertens. 13(3), 290-297 (2000).
47. Ball SG, White WB: Debate: anglotensin-converting enzyme inhibitors versus angiotensin II receptor blockers - a gap in evidence-based medicine. Am. J Cardiol. 91(10A), G15-G21 (2003).
48. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA. Saad MJ: Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46(12), 1950-1957
49. Henriksen EJ, Jacob S. Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ: ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am. J. Physiol. 277(1 Pt 2), R332-R336 (1999).
50. Mitch WE. Goldberg AL: Mechanisms of muscle wasting - the role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335(25), 1897-1905 (1996).
51. Roubenoff R, Ran LC: Humoral mediation of changing body composition during aging and chronic inflammation. Nutr. Rev. 51(1), 1-11 (1993).
52. Cohen HJ, Pieper CF, Harris T, Rao KM. Currie MS: The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol. A Biol. Sci. Med. Sci. 52(4), M201-M208 (1997).
53. Ferrucci L, Harris TB, Guralnik JM et al.: Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc. 47(6), 639-646 (1999).
54. Harris TB. Ferrucci L, Tracy RP et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106(5), 506-512 (1999).
55. Penninx BW, Kritchevsky SB, Newman AB et al.: Inflammatory markers and incident mobility limitation in the elderly. J. Am. Geriatr. Soc. 52(7), 1105-1113 (2004).
56. Reid MB. Li YP: Tumor necrosis factor-α and muscle wasting: a cellular perspective. Respir. Res. 2(5), 269-272 (2001).
57. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argoes JM: TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem. Biophys. Res. Commun. 230(2), 238-241 (1997).
58. Ebisui C, Tsujinaka T, Morimoto T et al.: Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin. Sci. (Lond.) 89(4). 431-439 (1995).
59. Tsujinaka T, Fujita J, Ebisui C et al.: Interleukin 6 receptor antibody Inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Invest. 97(1), 244-249 (1996).
60. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ. Res. 84(6). 695-703 (1999).
61. Campbell DJ: Circulating and tissue anglotensin systems. J. Clin. Invest. 79(1), 1-6 (1987).
62. Muller FL, Lustgarten MS, Jang Y, Richardson A, Van RH: Trends in oxidative aging theories. Frre Radic. Biol. Med. 43(4), 477-503 (2007).
63. Fulle S, Protasi F, Di TG, Pietrangelo T, Beltramin A, Boncompagni S. Vecchiet L, Fano G: The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp. Gerontol. 39(1), 17-24 (2004).
64. Bua EA, McKiernan SH, Wanagat J, McKenzie D, Aiken JM: Mitochondrial. abnormalities are more frequent in muscles undergoing sarcopenia. J. Appl. Physiol. 92(6), 2617-2624 (2002).
65. Pak JW, Herbst A. Bua E, Gokey N, McKenzie D, Aiken JM: Mitochondrial DNA mutations as a fundamental mechanism in physiological declines associated with aging. Aging Cell 2(1), 1-7 (2003).
66. Hepple RT, Hagen JL, Krause DJ, Jackson CC: Aerobic power declines with aging in rat skeletal muscles perfused at matched convective O2 delivery. J. Appl. Physol.. 94(2), 744-751 (2003).
67. Rasmussen UF. Krustrup P, Kjaer M, Rasmussen HN: Experimental evidence against the mitochondrial theory of aging. A study of isolated human skeletal muscle mitochondria. Exp. Gerontol. 38(8), 877-886 (2003).
68. de Cavanagh EM, Piotrkowski B, Basso N et al.: Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 17(9), 1096-1098 (2003).
69. Burlew B: Diastolic dysfunction In the elderly - the interstitial issue. Am. J. Geriatr. Cardiol. 13, 29-38 (2004).
70. Kitzman D, Scholz D, Hagen P et al.: Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity), A qualitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin. Proc. 63, 137-146 (1988).
71. Zieman S, Melenovsky V, Kass D: Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25(5), 932-943 (2005).
72. Chobanian AV: Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med. 357(8), 799-796 (2007).
73. Heymes C, Swynghedauw B, Chevalier B: Activation of angiotensin and anglotensin-converting enzymegene expression in the left ventricle of senescent-rats. Circulation 90, 1328-1333 (1994).
74. Heymes C, Silvestre PS, Llorens-Cortes C et al.: Cardiac senescence is associated with enhanced expresion of angiotensin, II receptor subtypes. Endocrinology 139. 2579-2587 (1998).
75. Lacolley P, Safar M, Lucet B et al.: Prevention of aortic and cardiac fibrosis by spinolactone in old normotensive rat. J. Am. Coll. Cardiol. 37, 662-667 (2001).
76. Sadoshima J, Izumo S: Molecular characterization of anglotensin II-induced hypertrophy of cardiac myocytes and hyperplasla of cardiac fibrolasts. Critical role of the AT1 reoeptor subtype. Circ. Res. 73, 413-423 (1993).
77. Schorb W, Booz W, Dostal D et al.: Angiatensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ. Res. 72, 1245-1254 (1993).
78. Sun Y, Zhang J, Lu L et al.: Tissue angiotensin II In the regulation of inflammattory and fibrogenic components of repair in the rat heart. J Lab. Clin. Med. 143, 41-51 (2004).
79. Delcayre C, Silvestre J, Garnier A: Cardiac alclosterone production and ventricular remodeling. Kidney Int. 57, 1346-1351 (2000).
80. Dostal DBK: The cardiac renin-angtotensin system: conceptual, or a regulator of cardiac function? Circ. Res. 85, 643-650 (1999).
81. Yusuf S, Pfeffer M, Swedberg K et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preseryed Trial. Lancet 362, 777-781 (2003).
82. Carson P, Massie B, McKeivie R et al.: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J. Card. Fall. 11, 576-585 (2005).
83. Cleland J, Tendera M, Adamus J et al.: The Perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 27, 2338-2345 (2006).
84. Weber KT: Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease? Congest. Heart Fail., 11(6), 322-324 (2005).
85. Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F: Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension. 19(Suppl. 2), 11237-11242 (1992).
86. Tufro-McRecreddie A, Romano LN, Harts JM, Ferder L, Gomez RA: Angiotensin II regulates nephrogenesis and renal vascular development. Am. J. Physiol. 269 (1 Pt 2), Fe110-F115 (1995).
87. Inserra F, Romano L, Ercole L, de Cavanagh EMV, Ferder L: Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension 25(3), 437-442 (1995).
88. Ferrier L, Inserra F. Romano L, Ercole L, Pszenny V: Decreased glomerulosclerosis in aging by angiotensin-converting enzyme inhibitors. J Am. Soc. Nephrol. 5(4), 1147-1152 (1994).
89. Ferder LF, Inserra F, Daccordi H, mith RD: Enalapril improved renai function and proteinuria in chronic glomerulopathies. Nepbron 55(Suppl 1). 90-95 (1990).
90. Inserra F. Romano LA, de Cavanagh EM, Ercole L, Ferder LF, Gomez RA. Renal Interstitial sclerosis in aging: effects of enalapril and nifedipine. J. Am. Soc. Nephrol.. 7(5), 676-680 (1996).
91. Pilote L, Abrahamowitz M, Rodrigues E., Eisenberg MJ, Rahme E: Mortality rates in elderJy patients who take different anglotensin-converting enzyme Inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 141(2), 102-112 (2004).
92. Latini R, Masson S. Staszewsky L, Maggioni PF: Valsartan for the treatment of heart failure. Expert Opin Pharmacother. 5(1). 181-193 (2004).
93. Pfeffer MA, McMurray JJV. Velazquez EJ et al.: for the Valsartan in Acute Myocardial Infarction Trial investigators: Valsartan, captopril, or bboth in myocardial infarction complicated by heart failurre, left ventricular dysfunction or both. N. Engl. J. Med. 349(20). 1893-1906 (2003).